Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus brevis CD2 in mild to moderate periodontitis
NCT02203812Phase 3Completed
- Sponsor
- CD Pharma Group
- Start
- Jan 2015
- Primary completion
- Feb 2016
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
A Phase 3 trial of lactobacillus brevis cd2 in chronic periodontitis, sponsored by CD Pharma Group. Started Jan 2015; status: completed.
02
Drugs
lactobacillus brevis cd2
03
Conditions
chronic periodontitis
Beyond the preview
Go deeper on NCT02203812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02203812.